Impact of EPAG treatment on candidate gene mutations. The percentage of variant alleles is shown on the y-axis at baseline and the primary end point (3 months for study 1, 6 months for study 2) for mutations detected in 63 candidate genes in all analyzed patients (n = 64; A), responding patients (n = 26; B), cytogenetic evolvers (n = 12; C), and nonresponding patients (n = 26; D). P values for paired Student t tests comparing baseline and end point are shown.